Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (131-140 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenaseS D Baker, S P Khor, A A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracilS D Baker, R B Diasio, S O'Reilly, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samplesS H Kaufmann, S D Gore, L Letendre, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
British Journal of Cancer|January 6, 2011
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancerJ B Baker, D Dutta, D Watson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependenceE K Rowinsky, S H Kaufmann, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignanciesL A Hammond, J R Eckardt, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2000
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignanciesL Ochoa, H I Hurwitz, G Wilding, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancerA Patnaik, E K Rowinsky, B K Tammara, et al.
Pageof 16

Showing results (131-140 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenaseS D Baker, S P Khor, A A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracilS D Baker, R B Diasio, S O'Reilly, et al.
Annals of the New York Academy of Sciences|December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samplesS H Kaufmann, S D Gore, L Letendre, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
British Journal of Cancer|January 6, 2011
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancerJ B Baker, D Dutta, D Watson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependenceE K Rowinsky, S H Kaufmann, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignanciesL A Hammond, J R Eckardt, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2000
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignanciesL Ochoa, H I Hurwitz, G Wilding, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancerA Patnaik, E K Rowinsky, B K Tammara, et al.
Pageof 16